On the surface, we’re a dedicated group of scientists with a novel therapeutic that we hope will provide patients with a better tomorrow. Whether we’re at the lab running experiments or applying for grants, our startup has been operating since 2016, and this is just the beginning.
A PEPTIDE THAT INHIBITS FUNCTION OF MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE (MARCKS) REDUCES LUNG CANCER METASTASIS
July 10, 2014
New Horizons In Therapy
NOVEL THERAPIES FOR OLD PROBLEMS
At Effectorbio, translational medicine is at our core. We are focused on the therapeutics of tomorrow, and our main goal is bringing discoveries from the bench to bedside. The critical aspect of our company is to propel preclinical findings into clinical trials that will help build a better tomorrow for everyone.
Effectorbio Inc has been awarded multiple grants since 2016 and is currently pursuing support from the National Institutes of Health (NIH) small business grants.
We have developed a novel 25-mer therapeutic peptide drug targeting the MARCKS Phosphorylation Site domain (MPS). Studies have shown promising results in suppressing multiple human diseases including but not limited to cancer, asthma, and pulmonary fibrosis.
Currently, the company is supported by various grants from both domestic and abroad. We are looking for partners interested in developing novel therapeutics in the areas of cancer and inflammatory pulmonary diseases.